Cancer News

Pediatric MATCH Trial to Test Targeted Drugs in Childhood Cancers (08/02/2017)

Today investigators at the National Cancer Institute (NCI) and the Children’s Oncology Group (COG) announced the opening of enrollment for a unique precision medicine clinical trial. NCI-COG Pediatric Molecular Analysis for Therapy Choice (Pediatric MATCH) is a nationwide trial to explore whether targeted therapies can be effective for children and adolescents with solid tumors that …

Continue reading "Pediatric MATCH Trial to Test Targeted Drugs in Childhood Cancers"

Penn Study Suggests that Combining CAR T Cells with Existing Immunotherapies May Overcome Resistance in Glioblastomas (07/24/2017)

Donald M. O’Rourke, MD Genetically modified “hunter” T cells successfully migrated to and penetrated a deadly type of brain tumor known as glioblastoma (GBM) in a clinical trial of the new therapy, but the cells triggered an immunosuppressive tumor microenvironment and faced a complex mutational landscape that will need to be overcome to better treat …

Continue reading "Penn Study Suggests that Combining CAR T Cells with Existing Immunotherapies May Overcome Resistance in Glioblastomas"

Addition of Temodar® to Radiation in Glioma: New Standard of Care (01/19/2017)

The addition of the chemotherapy agent, Temodar® (temozolomide), to radiation therapy has demonstrated a huge survival benefit compared to treatment with radiation therapy alone among patients with newly diagnosed glioma. These results were recently presented at the 2016 annual meeting of the American Society of Clinical Oncology. Gliomas refer to a class of brain cancers. …

Continue reading "Addition of Temodar® to Radiation in Glioma: New Standard of Care"

Temodar® After Radiation Improves Survival in Anaplastic Gliomas (06/07/2016)

The use of the chemotherapy agent Temodar (temozolomide) following radiation therapy significantly improves time to cancer progression and overall survival among patients with newly diagnosed anaplastic glioma without 1p/19q co-deletions. These results were recently presented at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO). Anaplastic gliomas are a type of brain … Continue reading "Temodar® After Radiation Improves Survival in Anaplastic Gliomas"

Genetically Modified Poliovirus Granted “Breakthrough” by FDA for Glioblastoma (05/23/2016)

The United States Food and Drug Administration (FDA) has granted “breakthrough status” designation for the treatment of glioblastoma containing a genetically modified poliovirus. Glioblastoma is an extremely aggressive form of brain cancer, with few patients surviving 5 years following diagnosis. Despite efforts with surgery, chemotherapy, and/or radiation therapy, the overall outcomes for patients with glioblastoma … Continue reading "Genetically Modified Poliovirus Granted “Breakthrough” by FDA for Glioblastoma"

Avastin®/Camptosar® Improves Outcomes Compared with Temodar® in Glioblastoma (05/12/2016)

The treatment combination consisting of Avastin (bevacizumab) plus Camptosar (irinotecan) improves time to cancer progression compared to treatment with Temodar (temozolomide) in patients with newly diagnosed glioblastoma. These results were recently published in the Journal of Clinical Oncology. Glioblastoma is an extremely aggressive form of brain cancer. Standard therapy includes surgery to remove as much … Continue reading "Avastin®/Camptosar® Improves Outcomes Compared with Temodar® in Glioblastoma"

Immune Therapy for Brain Tumors: A New Promising Avenue (02/17/2016)

  Glioblastoma is a particularly aggressive type of brain cancer. Only about one fifth of adults diagnosed with it survive two years or more after their diagnosis. A new two-drug combination, currently in early clinical trials, might help people diagnosed with glioblastoma to fight the disease. In a presentation of early clinical trial data to … Continue reading "Immune Therapy for Brain Tumors: A New Promising Avenue"